title: The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
abstract: Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.
authors.affiliation: Haematology Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.forename: Mark
authors.initials: M
authors.lastname: Bishton
authors.forename: Simon
authors.initials: S
authors.lastname: Harrison
mesh_terms: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D007211:Indoles; D009101:Multiple Myeloma / Q000188:drug therapy*; D000077767:Panobinostat; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat; C502418:givinostat hydrochloride